Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...
On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts.
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to ...
Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib’s clinical progress and de-risking. Click here to read my ...
The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.
Asianet Newsable on MSN
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer
The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback